Compare ABR & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABR | VCEL |
|---|---|---|
| Founded | 2003 | 1989 |
| Country | United States | United States |
| Employees | 653 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 1996 |
| Metric | ABR | VCEL |
|---|---|---|
| Price | $7.36 | $29.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $10.30 | ★ $58.50 |
| AVG Volume (30 Days) | ★ 4.1M | 610.3K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 15.87% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.10 |
| Revenue Next Year | N/A | $17.95 |
| P/E Ratio | ★ $9.29 | $96.31 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $7.11 | $29.24 |
| 52 Week High | $12.58 | $45.97 |
| Indicator | ABR | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 30.35 |
| Support Level | $7.23 | N/A |
| Resistance Level | $8.07 | $38.48 |
| Average True Range (ATR) | 0.23 | 1.52 |
| MACD | -0.06 | -0.18 |
| Stochastic Oscillator | 4.17 | 9.09 |
Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily, SFR, and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.